Skip to main content

Life Sciences is now live. See how →

Patent Examiner Robert H. Havlin

Art Unit 1626 · Heterocyclic Drug Compounds, Synthesis & Therapeutic Uses · Tech Center 1600 · 267 applications filed 2021–2026

⚑ Extremely Hard · harder than 96% of examiners● Free examiner data

Robert H. Havlin is a USPTO patent examiner in Art Unit 1626 (Heterocyclic Drug Compounds, Synthesis & Therapeutic Uses) with 267 applications from filing years 2021–2026. Examiner Havlin's allowance rate is 30.1%, below the 82.1% USPTO average for applications filed in the same years. The examiner ranks harder than 96% of examiners. In 2021, decided applications with an examiner interview were allowed 76.4 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Extremely Hard
harder than 96% of examiners
Easier96th percentileHarder
Allowance rate vs peers
Examiner Havlin30.1%
Art Units 1622, 1626, 1675, and 169270.2%
USPTO average82.1%
Allowance rate
30.1%
▼ USPTO avg 82.1%
Applications
267
filing years 2021–2026
First-action allowance
6.5%
patented with no rejection
Abandoned
24.3%
share of applications
Avg office actions
1.4
USPTO avg 1.2
Days to first OA
774
▲ USPTO 580
RCE rate
18.0%
USPTO 17.6%
Interview rate
15.7%
USPTO 24.5%

Examiner details

  • Art unit1626 · Heterocyclic Drug Compounds, Synthesis & Therapeutic Uses
  • Title / gradeSupervisory Patent Examiner · GS-15
  • Service20 years
  • PhoneOn each office action
  • Email[email protected]
  • In USPTO recordsHAVLIN, ROBERT H
Full signatory authority

Examiner Havlin can allow an application without a supervisory sign-off.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions424 · Drug, Bio-Affecting & Body Treating Compositions506 · Combinatorial Chemistry Technology (Method, Library, Apparatus)

How to improve your odds with Examiner Havlin

  • The data favors an interview. Interviewed cases were allowed more often in both measured years, by 45.6 to 76.4 points.
  • Plan for the timeline. First office action averages 774 days vs the 580-day USPTO norm.
  • Expect a §103. Obviousness is the most-issued rejection (103), and applicants overcame it 39.1% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 4.0 to 45.6 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§102 Novelty77 issued · 54.3% overcome
§103 Obviousness103 issued · 39.1% overcome
§112 Definiteness & disclosure72 issued · 55.6% overcome
How applicants traverse §103 rejections🔒 Members

Applicants overcame 18 of the 46 decided §103 obviousness rejections from Examiner Havlin in the data. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §103 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Havlin?

Draft your response with Examiner Havlin's record and Art Unit 1626's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response workflow.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Havlin.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202226.4%66.7%21.1%+45.6pp
202130.8%42.9%38.9%+4.0pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/253704Triazine Dione Derivative, Preparation Method Therefor and Application Thereof in MedicinePatented1🔒 View
18/173386Nucleic Acid Extraction and Amplification Controls and Methods of Use ThereofAbandoned2🔒 View
18/001002Quinazoline Derivatives Useful as Selective HDAC6 InhibitorsPatented2🔒 View
17/915608Methods and Pharmaceutical Compositions of Thromboxane A2 Receptor Antagonist for the Treatment of COVID-19Abandoned3🔒 View
See all 267 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1626 technology

Azoles & pyrrolesPyrimidines & other diazinesKinase & enzyme inhibitorsMethods of treatmentTop CPC C07D · A61K · C07C
About this examiner. Robert H. Havlin examines in Art Unit 1626 (Heterocyclic Drug Compounds, Synthesis & Therapeutic Uses, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Robert H. Havlin's allowance rate?
Examiner Havlin's allowance rate is 30.1%, compared with 82.1% across the USPTO and 70.2% in Art Units 1622, 1626, 1675, and 1692 for applications filed in the same years. That rate ranks Examiner Havlin harder than 96% of examiners.
Is Examiner Havlin a hard examiner?
Yes, markedly. Examiner Havlin ranks harder than 96% of examiners, in the 96th difficulty percentile (extremely hard). Examiner Havlin has a 30.1% allowance rate versus 82.1% across the USPTO and 70.2% in Art Units 1622, 1626, 1675, and 1692, 1.4 office actions per application versus 1.2, and an RCE rate of 18.0% versus 17.6% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Havlin?
In this examiner's record, yes. Decided applications with an interview were allowed more often in both measured years, by 45.6 to 76.4 percentage points. In 2021, 88.9% of decided applications with an interview were allowed, versus 12.5% of those without.
What is Examiner Havlin's most common rejection?
§103 obviousness, issued 103 times in the data. Applicants overcame it 39.1% of the time.
Is an RCE worth filing with Examiner Havlin?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in both measured years, by 4.0 to 45.6 percentage points. In 2021, 42.9% of decided applications with an RCE were allowed, versus 38.9% of those without one.
How long until the first office action from Examiner Havlin?
About 774 days on average, versus 580 days across the USPTO for applications filed in the same years.
How do I contact Examiner Robert H. Havlin?
Examiner Havlin can be reached by email at [email protected]. The examiner's direct line is listed at the end of the examiner's office actions.

Put Examiner Havlin's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Robert H. Havlin, or see an error? Request a correction.